Clinical trial Recruiting at 2 sites Interventional Ages 18 to 70

Oral vitamin C to promote health in middle-aged and older adults

Official title: Randomized Controlled Trial on Vitamin C Supolementation for HealthRegulation in Middle-Aged and Elderly Adults

Run by Peking University Third Hospital · NCT06794255 · Data updated 2026-11-12

This trial will test whether taking oral vitamin C daily for 12 months can slow aging-related changes in generally healthy people aged 55–65.

More Ageing trials

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment400 (estimated)
SponsorPeking University Third Hospital
Academic / other
Drugs / interventionschemotherapy
Locations3 sites (Nanchang, Jiangxi and 2 other locations)
StatusRecruiting
StartedApril 2, 2025
Main results expectedJanuary 30, 2026
Study endsJanuary 30, 2027
Registry record updatedJune 27, 2025
Trial IDNCT06794255 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are generally healthy adults aged 55–65 with BMI 18.5–28 kg/m² who can give informed consent and comply with study visits and dosing for 12 months.

Probably not a fit

People with uncontrolled chronic or severe diseases (for example cancer, heart failure, renal insufficiency, poorly controlled hypertension, active liver disease), those outside the BMI or age ranges, or those with contraindications listed in the exclusion criteria are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, placebo-controlled interventional trial gives participants oral vitamin C or a matching placebo for 12 consecutive months and compares aging-related indicators and safety outcomes. Participants are asked to take two 250 mg tablets after breakfast and dinner each day and attend face-to-face follow-ups every 6 months with telephone check-ins every 2 months. Researchers will measure a panel of candidate biomarkers of human aging alongside routine safety labs and cardiac monitoring to identify sensitive indicators and monitor adverse events. A baseline control cohort with a wider age range is included to characterize normal aging changes.

Why it matters

Potential benefit: If successful, daily vitamin C could offer a low-cost, widely available way to slow some measurable aspects of aging and guide future small-molecule interventions.

How similar studies have gone: Some observational studies and small trials have linked antioxidant vitamins to changes in aging biomarkers, but high-quality randomized evidence that vitamin C delays human aging is limited and mixed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).
* Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
* Weight: BMI within the range of 18.5-28 kg/m².
* Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.

Exclusion Criteria:

* Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.).
* Weight: BMI \< 18.5 or BMI \> 28.
* Substance/Alcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption.
* Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria.
* Allergy: Allergy to vitamin C or any component of its formulation.
* Recent Medication Use: Use of high-dose vitamin C, vitamin E, low-dose aspirin, acarbose, metformin, NMN/NR, or other anti-aging/weight-loss drugs within the past 3 months.
* Informed Consent: Inability to provide informed consent.
* Other: Any physical condition that, in the investigator's opinion, may adversely affect the study process or outcomes.
* Clinical Research Participation: Participation in any other clinical research within 3 months prior to screening or during the study period, or receipt of chemotherapy, radiotherapy, biologic therapy, small-molecule therapeutic agents, or investigational drugs, with incomplete recovery from related side effects (excluding alopecia or potential neuropathy).

Where it's running

  • The first affiliated hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
  • People's Hospital of Quzhou
    Quzhou, Zhejiang, China
    Recruiting
  • Peking University Third Hospital
    Beijing, China
    Enrolling by invitation

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.